melatonin has been researched along with Chronic Fatigue and Immune Dysfunction Syndrome in 17 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aim of the study was to determine the possible effect of melatonin treatment on disturbed sleep, fatigue and pain symptoms observed in fibromyalgia (FM) patients." | 9.09 | The effect of melatonin in patients with fibromyalgia: a pilot study. ( Arias, MA; Brusco, LI; Cardinalli, DP; Citera, G; Lázaro, MA; Maldonado-Cocco, JA; Rosemffet, MG; Scheines, EJ, 2000) |
| "The pathophysiology of chronic fatigue syndrome is unknown, however activation of immune, inflammatory, oxidative and nitrosative stress mechanisms and plasma lipid peroxide elevation was reported." | 6.82 | Effect of melatonin supplementation on plasma lipid hydroperoxides, homocysteine concentration and chronic fatigue syndrome in multiple sclerosis patients treated with interferons-beta and mitoxantrone. ( Adamczyk, J; Adamczyk-Sowa, M; Misiolek, H; Niedziela, N; Owczarek, M; Sowa, P; Zwirska-Korczala, K, 2016) |
| "Fibromyalgia (FM) and chronic fatigue syndrome (CFS) are stress associated disorders mainly affecting women." | 5.30 | Melatonin levels in women with fibromyalgia and chronic fatigue syndrome. ( Brucksch, C; Crofford, L; Demitrack, MA; Engelberg, NC; Haus, E; Korszun, A; Masterson, L; Papadopoulos, E; Sackett-Lundeen, L, 1999) |
| "The aim of the study was to determine the possible effect of melatonin treatment on disturbed sleep, fatigue and pain symptoms observed in fibromyalgia (FM) patients." | 5.09 | The effect of melatonin in patients with fibromyalgia: a pilot study. ( Arias, MA; Brusco, LI; Cardinalli, DP; Citera, G; Lázaro, MA; Maldonado-Cocco, JA; Rosemffet, MG; Scheines, EJ, 2000) |
| "To assess urinary 6-sulphatoxymelatonin levels in a large consecutive series of patients with migraine and several comorbidities (chronic fatigue, fibromyalgia, insomnia, anxiety, and depression) as compared with controls." | 3.76 | Urinary 6-sulphatoxymelatonin levels are depressed in chronic migraine and several comorbidities. ( Cipolla-Neto, J; de Souza Vieira, DS; Lin, J; Masruha, MR; Minett, TS; Peres, MF; Vilanova, LC; Zukerman, E, 2010) |
| "The pathophysiology of chronic fatigue syndrome is unknown, however activation of immune, inflammatory, oxidative and nitrosative stress mechanisms and plasma lipid peroxide elevation was reported." | 2.82 | Effect of melatonin supplementation on plasma lipid hydroperoxides, homocysteine concentration and chronic fatigue syndrome in multiple sclerosis patients treated with interferons-beta and mitoxantrone. ( Adamczyk, J; Adamczyk-Sowa, M; Misiolek, H; Niedziela, N; Owczarek, M; Sowa, P; Zwirska-Korczala, K, 2016) |
| "Patients with chronic fatigue syndrome (CFS) show evidence of circadian rhythm disturbances." | 2.70 | Therapy of circadian rhythm disorders in chronic fatigue syndrome: no symptomatic improvement with melatonin or phototherapy. ( Hayden, K; Minors, D; Mugarza, J; Waterhouse, J; Williams, G, 2002) |
| "Melatonin has been also used as a complementary treatment in anaesthesia, hemodialysis, in vitro fertilization and neonatal care." | 2.46 | Clinical uses of melatonin: evaluation of human trials. ( Mediavilla, MD; Reiter, RJ; Sánchez-Barceló, EJ; Tan, DX, 2010) |
| "Fibromyalgia (FM) and chronic fatigue syndrome (CFS) are stress associated disorders mainly affecting women." | 1.30 | Melatonin levels in women with fibromyalgia and chronic fatigue syndrome. ( Brucksch, C; Crofford, L; Demitrack, MA; Engelberg, NC; Haus, E; Korszun, A; Masterson, L; Papadopoulos, E; Sackett-Lundeen, L, 1999) |
| "Many patients with chronic fatigue syndrome (CFS) display features of hypothalamic dysfunction." | 1.29 | Dissociation of body-temperature and melatonin secretion circadian rhythms in patients with chronic fatigue syndrome. ( Arendt, J; Buchan, I; Edwards, RH; Minors, D; Pirmohamed, J; Waterhouse, J; Williams, G, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (23.53) | 18.2507 |
| 2000's | 7 (41.18) | 29.6817 |
| 2010's | 5 (29.41) | 24.3611 |
| 2020's | 1 (5.88) | 2.80 |
| Authors | Studies |
|---|---|
| Cardinali, DP | 1 |
| Brown, GM | 1 |
| Pandi-Perumal, SR | 1 |
| Datieva, VK | 1 |
| Rosinskaia, AV | 1 |
| Levin, OS | 1 |
| Pardini, M | 1 |
| Cordano, C | 1 |
| Benassi, F | 1 |
| Mattei, C | 1 |
| Sassos, D | 1 |
| Guida, S | 1 |
| Serrati, C | 1 |
| Primavera, A | 1 |
| Amore, M | 1 |
| Cocito, L | 1 |
| Emberti Gialloreti, L | 1 |
| Adamczyk-Sowa, M | 1 |
| Sowa, P | 1 |
| Adamczyk, J | 1 |
| Niedziela, N | 1 |
| Misiolek, H | 1 |
| Owczarek, M | 1 |
| Zwirska-Korczala, K | 1 |
| Masruha, MR | 1 |
| Lin, J | 1 |
| de Souza Vieira, DS | 1 |
| Minett, TS | 1 |
| Cipolla-Neto, J | 1 |
| Zukerman, E | 1 |
| Vilanova, LC | 1 |
| Peres, MF | 1 |
| Sánchez-Barceló, EJ | 1 |
| Mediavilla, MD | 1 |
| Tan, DX | 1 |
| Reiter, RJ | 1 |
| Williams, G | 2 |
| Waterhouse, J | 2 |
| Mugarza, J | 1 |
| Minors, D | 2 |
| Hayden, K | 1 |
| Singh, A | 2 |
| Naidu, PS | 1 |
| Gupta, S | 2 |
| Kulkarni, SK | 2 |
| Garg, V | 1 |
| van Heukelom, RO | 1 |
| Prins, JB | 1 |
| Smits, MG | 2 |
| Bleijenberg, G | 1 |
| Miike, T | 1 |
| Pirmohamed, J | 1 |
| Buchan, I | 1 |
| Arendt, J | 1 |
| Edwards, RH | 1 |
| Nagtegaal, JE | 1 |
| Swart, AC | 1 |
| van de Luit, L | 1 |
| van der Meulen, J | 1 |
| Cleophas, TJ | 1 |
| Zwinderman, AH | 1 |
| Korszun, A | 1 |
| Sackett-Lundeen, L | 1 |
| Papadopoulos, E | 1 |
| Brucksch, C | 1 |
| Masterson, L | 1 |
| Engelberg, NC | 1 |
| Haus, E | 1 |
| Demitrack, MA | 1 |
| Crofford, L | 1 |
| Citera, G | 1 |
| Arias, MA | 1 |
| Maldonado-Cocco, JA | 1 |
| Lázaro, MA | 1 |
| Rosemffet, MG | 1 |
| Brusco, LI | 1 |
| Scheines, EJ | 1 |
| Cardinalli, DP | 1 |
| Knook, L | 1 |
| Kavelaars, A | 1 |
| Sinnema, G | 1 |
| Kuis, W | 1 |
| Heijnen, CJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| "Melatonin for Migraine Prevention in Adolescents: A Pilot Remote Trial: The BRAiN-M Study"[NCT02344316] | Phase 2 | 31 participants (Actual) | Interventional | 2015-05-31 | Completed | ||
| Melatonin for Adolescent Migraine Prevention Study (The MAP Study).[NCT03150797] | Phase 2 | 72 participants (Actual) | Interventional | 2017-08-02 | Terminated (stopped due to Insufficient Fund) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Number of participants that had ≥85% headache diary compliance during weeks 12-16 of the study. (NCT02344316)
Timeframe: Weeks 12-16 of the study
| Intervention | Participants (Count of Participants) |
|---|---|
| Melatonin | 11 |
| Placebo | 10 |
eCAP tack caps will be used to measure medication adherence and the number of openings will be recorded per participant. (NCT02344316)
Timeframe: "during the At Home Active Study Period or Weeks 5-16"
| Intervention | Mean Number of Openings (Mean) |
|---|---|
| Melatonin | 39 |
| Placebo | 60 |
Number of Migraine/Migrainous Days Per 28 Day Period in melatonin group and placebo group as measured using an online/mobile device headache diary. (NCT02344316)
Timeframe: final 4 weeks of treatment
| Intervention | days (Mean) |
|---|---|
| Melatonin | 3.6 |
| Placebo | 4.9 |
Number of minutes to sleep onset as measured by a FitBit. (NCT02344316)
Timeframe: 16 weeks
| Intervention | minutes (Mean) |
|---|---|
| Melatonin | 15.2 |
| Placebo | 17.2 |
Change in mean migraine/migrainous days from weeks 5-8 of single-blind treatment phase to weeks 5-8 of randomized treatment phase for each group. (Medians reported when data were not normally distributed). (NCT03150797)
Timeframe: Weeks 5-8 of single-blind treatment phase to weeks 5-8 of randomized treatment phase.
| Intervention | days (Median) |
|---|---|
| Melatonin 3mg | 2 |
| Melatonin 6mg | -1 |
| Placebo Oral Capsule | 0 |
Mean CASQ score in weeks 5-8 of randomized treatment phase in melatonin treated group vs. placebo, and in each of the three pair-wise group comparisons. The CASQ is a 16-question instrument that uses Likert-like responses and has a score range from 16-80; higher scores indicate greater sleepiness (NCT03150797)
Timeframe: Weeks 5-8 of randomized treatment phase.
| Intervention | points (Mean) |
|---|---|
| Melatonin 3mg | 33 |
| Melatonin 6mg | 36 |
| Placebo Oral Capsule | 28 |
Mean migraine/migrainous days in weeks 5-8 of randomized treatment phase in melatonin 3 mg vs. placebo. (NCT03150797)
Timeframe: Weeks 5-8 of randomized treatment phase.
| Intervention | days (Median) |
|---|---|
| Melatonin 3mg | 2 |
| Melatonin 6mg | 2 |
| Placebo Oral Capsule | 2 |
Mean migraine/migrainous days in weeks 5-8 of randomized treatment phase in melatonin 6 mg vs. melatonin 3 mg. (NCT03150797)
Timeframe: Weeks 5-8 of randomized treatment phase.
| Intervention | days (Median) |
|---|---|
| Melatonin 3mg | 2 |
| Melatonin 6mg | 2 |
| Placebo Oral Capsule | 2 |
Mean migraine/migrainous days in weeks 5-8 of randomized treatment phase in melatonin 6 mg vs. placebo. (Medians reported when data were not normally distributed). (NCT03150797)
Timeframe: Weeks 5-8 of randomized treatment phase.
| Intervention | days (Median) |
|---|---|
| Melatonin 3mg | 2 |
| Melatonin 6mg | 2 |
| Placebo Oral Capsule | 2 |
Mean migraine/migrainous days in weeks 5-8 of randomized treatment phase in melatonin treated participants vs. placebo. (Ultimately, as the data were not normally distributed, medians were more appropriate). (NCT03150797)
Timeframe: weeks 5-8 of randomized treatment phase
| Intervention | days (Median) |
|---|---|
| Melatonin 3mg | 2 |
| Melatonin 6mg | 2 |
| Placebo Oral Capsule | 2 |
Number of days acute medication is used in weeks 5-8 of randomized treatment phase in melatonin treated group vs. placebo, and in each of the three pair-wise group comparisons. This refers to the number of days that medication for the acute treatment of headache was used during the time frame. (NCT03150797)
Timeframe: Weeks 5-8 of randomized treatment phase.
| Intervention | days (Median) |
|---|---|
| Melatonin 3mg | 5 |
| Melatonin 6mg | 3 |
| Placebo Oral Capsule | 3 |
Number of headache days in weeks 5-8 of randomized treatment phase in melatonin treated group vs. placebo, and in each of the three pair-wise group comparisons. This refers to number of headache days during the time period--regardless of whether they were migraine or not. (NCT03150797)
Timeframe: Weeks 5-8 of randomized treatment phase.
| Intervention | days (Median) |
|---|---|
| Melatonin 3mg | 8 |
| Melatonin 6mg | 4 |
| Placebo Oral Capsule | 5 |
3 reviews available for melatonin and Chronic Fatigue and Immune Dysfunction Syndrome
| Article | Year |
|---|---|
Possible Application of Melatonin in Long COVID.
Topics: COVID-19 Drug Treatment; Fatigue Syndrome, Chronic; Humans; Melatonin; Post-Acute COVID-19 Syndrome; | 2022 |
Clinical uses of melatonin: evaluation of human trials.
Topics: Cardiovascular Diseases; Clinical Trials as Topic; Communicable Diseases; Endocrine System Diseases; | 2010 |
[Childhood chronic fatigue syndrome].
Topics: Adolescent; Child; Drugs, Chinese Herbal; Fatigue Syndrome, Chronic; History, 20th Century; Humans; | 2007 |
7 trials available for melatonin and Chronic Fatigue and Immune Dysfunction Syndrome
| Article | Year |
|---|---|
[The use of melatonin in the treatment of chronic fatigue syndrome and circadian rhythm disorders in Parkinson's disease].
Topics: Central Nervous System Depressants; Chronobiology Disorders; Circadian Rhythm; Dose-Response Relatio | 2013 |
Agomelatine but not melatonin improves fatigue perception: a longitudinal proof-of-concept study.
Topics: Acetamides; Adult; Antidepressive Agents; Fatigue; Fatigue Syndrome, Chronic; Female; Follow-Up Stud | 2014 |
Effect of melatonin supplementation on plasma lipid hydroperoxides, homocysteine concentration and chronic fatigue syndrome in multiple sclerosis patients treated with interferons-beta and mitoxantrone.
Topics: Adult; Antioxidants; Brain; Dietary Supplements; Fatigue Syndrome, Chronic; Female; Homocysteine; Hu | 2016 |
Therapy of circadian rhythm disorders in chronic fatigue syndrome: no symptomatic improvement with melatonin or phototherapy.
Topics: Adult; Body Temperature Regulation; Circadian Rhythm; Contraindications; Fatigue Syndrome, Chronic; | 2002 |
Influence of melatonin on fatigue severity in patients with chronic fatigue syndrome and late melatonin secretion.
Topics: Circadian Rhythm; Drug Administration Schedule; Fatigue Syndrome, Chronic; Humans; Melatonin; Sleep | 2006 |
The effect of melatonin in patients with fibromyalgia: a pilot study.
Topics: Administration, Oral; Adult; Aged; Anticonvulsants; Fatigue Syndrome, Chronic; Female; Fibromyalgia; | 2000 |
High nocturnal melatonin in adolescents with chronic fatigue syndrome.
Topics: Adolescent; Child; Fatigue Syndrome, Chronic; Female; Humans; Male; Melatonin; Saliva; Sleep; Survey | 2000 |
7 other studies available for melatonin and Chronic Fatigue and Immune Dysfunction Syndrome
| Article | Year |
|---|---|
Urinary 6-sulphatoxymelatonin levels are depressed in chronic migraine and several comorbidities.
Topics: Adolescent; Adult; Aged; Anxiety Disorders; Biomarkers; Comorbidity; Depressive Disorder; Down-Regul | 2010 |
Urinary 6-sulphatoxymelatonin levels are depressed in chronic migraine and several comorbidities.
Topics: Adolescent; Adult; Aged; Anxiety Disorders; Biomarkers; Comorbidity; Depressive Disorder; Down-Regul | 2010 |
Urinary 6-sulphatoxymelatonin levels are depressed in chronic migraine and several comorbidities.
Topics: Adolescent; Adult; Aged; Anxiety Disorders; Biomarkers; Comorbidity; Depressive Disorder; Down-Regul | 2010 |
Urinary 6-sulphatoxymelatonin levels are depressed in chronic migraine and several comorbidities.
Topics: Adolescent; Adult; Aged; Anxiety Disorders; Biomarkers; Comorbidity; Depressive Disorder; Down-Regul | 2010 |
Effect of natural and synthetic antioxidants in a mouse model of chronic fatigue syndrome.
Topics: Animals; Antioxidants; Brain; Carbazoles; Carvedilol; Catalase; Disease Models, Animal; Fatigue Synd | 2002 |
Role of antioxidants in chronic fatigue syndrome in mice.
Topics: Animals; Antioxidants; Brain; Carbazoles; Carvedilol; Catalase; Disease Models, Animal; Fatigue Synd | 2002 |
Dissociation of body-temperature and melatonin secretion circadian rhythms in patients with chronic fatigue syndrome.
Topics: Adult; Body Temperature; Circadian Rhythm; Fatigue Syndrome, Chronic; Female; Humans; Male; Melatoni | 1996 |
[Chronic fatigue syndrome].
Topics: Adult; Antioxidants; Child; Diagnosis, Differential; Fatigue Syndrome, Chronic; Female; Humans; Mela | 1997 |
Amplified amplitudes of circadian rhythms and nighttime hypotension in patients with chronic fatigue syndrome: improvement by inopamil but not by melatonin.
Topics: Adult; Blood Pressure; Circadian Rhythm; Deoxyepinephrine; Fatigue Syndrome, Chronic; Female; Heart | 1998 |
Melatonin levels in women with fibromyalgia and chronic fatigue syndrome.
Topics: Adolescent; Adult; Circadian Rhythm; Fatigue Syndrome, Chronic; Female; Fibromyalgia; Humans; Hydroc | 1999 |